Orthofix Medical (NASDAQ: OFIX ) just reported results for the second quarter of 2024. Orthofix Medical reported earnings per share of 5 cents. This was above the analyst estimate for EPS of -19 cents. The company reported revenue of $198.62 million. This was 1.74% better than the analyst estimate for revenue of $195.23 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post OFIX Stock Earnings: Orthofix Medical Beats EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .

Orthofix Medical Inc. (NASDAQ:NASDAQ:OFIX) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ETCompany ParticipantsJulie Dewey - Chief IR and…

Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance. Recent Highlights Second quarter 2024 net sales of $198.6 million, an increase of 6% on a reported and constant currency basis compared to second quarter 2023 Bone Growth Therapies (BGT) net sales growth of 12% Jetzt den vollständigen Artikel lesen

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that the Company will participate in Canaccord Genuity''s 44th Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 14, 2024 at 2:30 pm ET. Interested parties can access the live and archived webcast of the presentation on the Investors section of the Orthofix Jetzt den vollständigen Artikel lesen

Orthofix Medical Inc.OFIX recently announced the receipt of FDA 510(k) clearance and the first U.S. implant of the Fitbone Transport and Lengthening System. The system is used to treat large bone defects in the femur and tib

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Michael Finegan as Chair of the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624766470/en/ Michael Finegan, Chair of the Orthofix Board of Directors. (Photo: Business Wire) Jetzt den vollständigen Artikel lesen

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Aviva McPherron as President of Global Operations and Quality. As a member of the Executive Leadership Team, McPherron will oversee strategy for the company’s operations, manufacturing, regulatory, clinical, and quality teams. This press release features multimedia. View the Jetzt den vollständigen Artikel lesen